Core G: Biomarker Core

核心 G：生物标志物核心

基本信息

批准号：
10647913
负责人：
Jennifer S Yokoyama
金额：
$ 60.47万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10647913
关键词：
Aging Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Amyloid beta-Protein Basic Science Biochemistry Biological Markers Blood Cell Culture Techniques Cells Clinical Clinical Research Collaborations Collection Communities DNA Data Data Storage and Retrieval Dementia Dermal Development Disease Doctor of Philosophy Early Diagnosis Education Epithelium Fibroblasts Foundations Frontotemporal Lobar Degenerations Functional disorder Future Generations Genetic Genetic Markers Genomics Genotype Goals Heterogeneity Human Human Genetics Image Infrastructure International Investigation Light Liquid substance Measurement Measures Mentors Mission Molecular Genetics Monitor Neurodegenerative Disorders Neurologist Online Systems Participant Patients Physicians Pilot Projects Plasma Positioning Attribute Privatization Procedures Productivity Research Research Personnel Research Project Grants Research Support Resources Risk Estimate Sampling Scientist Serum Specimen Standardization Training Translational Research Variant Work accurate diagnosis biomarker development biomarker discovery cell bank cell repository data management data submission disease heterogeneity exome sequencing experience genome-wide improved induced pluripotent stem cell innovation insight interest multidisciplinary neurofilament neuroimaging neuroimaging marker neuropathology novel novel strategies polygenic risk score proteostasis query tools recruit repository risk variant specific biomarkers success synergism tau Proteins tau-1 therapy development

项目摘要

In the past five years, the UCSF ADRC Biospecimens and Genetics sub-cores (as part of the Neuropathology Core) have experienced tremendous success with collection, banking, genotyping and dissemination of human biospecimens, contributing more samples to the National Cell Repository for Alzheimer’s Disease (NCRAD) than any other ADRC. This new, proposed Biomarker Core will build on these strengths to support the UCSF ADRC’s mission of improving the early and accurate diagnosis of neurodegenerative disease. By banking and sharing a large, longitudinal collection of exquisitely well-characterized patient and control plasma, CSF, DNA and fibroblasts, we will be positioned to support research projects locally, nationally and internationally. The Clinical Core will refer ADRC subjects for fluid and cell collection which will be collaborative managed by the Biomarker Core (for storage, analysis and sharing) and Data Management Core (for web-based query tools and safe and compliant data storage and deposition.) Information will be shared with the Neuroimaging and Neuropathology Cores to drive scientific insights into disease pathophysiology. This Core will continue to genotype all ADRC participants for risk genes and alleles in collaboration with UCLA. We propose to add baseline characterization of CSF to include total tau (T-tau), phospho-tau (P-tau) and Abeta 40 and 42. We will also expand the toolbox of Biomarkers through investigation of novel fluid and genetic biomarkers and characterization of AD and ADRD epithelial fibroblasts. In Aim 1 we collect, store, track, share and analyze human blood, plasma, CSF and dermal fibroblasts. In Aim 2 we leverage existing projects to expand the toolbox of biomarkers for neurodegenerative diseases. The goal of Aim 3 is to attract new scientists to and promote interest in biomarker-based clinical and translational research through education and support of pilot projects. These contributions are significant because they will both build the foundation and push the leading edge of productive and sustainable biomarker development in Alzheimer’s Disease and related disorders. Together, this repository will help investigators begin to unravel the heterogeneity of these disease with the ultimate goal of improving therapies.

在过去的五年中，UCSF ADRC 生物样本和遗传学子核心（作为神经病理学的一部分） Core）在人类基因组的收集、存储、基因分型和传播方面取得了巨大的成功生物样本，向国家阿尔茨海默病细胞存储库 (NCRAD) 提供的样本数量比任何其他 ADRC。这个新的、拟议的生物标志物核心将建立在这些优势的基础上，以支持 UCSF ADRC。使命是通过存储和共享来改善神经退行性疾病的早期和准确诊断。大量、纵向收集特征明确的患者和对照血浆、CSF、DNA 和成纤维细胞，我们将致力于支持本地、国内和国际的研究项目。 Core 将转介 ADRC 受试者进行液体和细胞收集，这些收集将由 Biomarker 协作管理核心（用于存储、分析和共享）和数据管理核心（用于基于网络的查询工具和安全可靠的工具）合规的数据存储和沉积。）信息将与神经影像和神经病理学共享推动对疾病病理生理学的科学见解的核心该核心将继续对所有 ADRC 进行基因分型。我们建议与加州大学洛杉矶分校合作，增加风险基因和等位基因的参与者。 CSF 的工具箱包括总 tau (T-tau)、磷酸化 tau (P-tau) 以及 Abeta 40 和 42。我们还将扩展工具箱通过研究新型液体和遗传生物标志物以及 AD 和 ADRD 的特征来研究生物标志物在目标 1 中，我们收集、存储、跟踪、共享和分析人类血液、血浆、脑脊液和真皮。在目标 2 中，我们利用现有项目来扩展神经退行性疾病生物标志物的工具箱。目标 3 的目标是吸引新科学家对基于生物标记的临床和疾病的兴趣。通过教育和支持试点项目进行转化研究，这些贡献是重大的。因为它们都将为高效和可持续生物标志物奠定基础并推动其前沿该存储库将帮助研究人员开始研究阿尔茨海默病和相关疾病的发展。揭示这些疾病的异质性，最终目标是改进治疗方法。